ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

HEMLIBRA
Bleeding disorders
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

HEMLIBRA Rx

Generic Name and Formulations:
Emicizumab-kxwh 30mg/mL, 60mg/0.4mL, 105mg/0.7mL, 150mg/mL; per vial; soln for SC inj; preservative-free.

Company:
Genentech, Inc.

Therapeutic Use:

Indications for HEMLIBRA:

Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A with factor VIII inhibitors.

Adults and Children:

Do not inj into moles, scars, tender skin, bruised, red, hard or not intact skin areas. Give by SC inj into upper outer arms, thighs, or any abdomen quadrant; rotate inj sites. 3mg/kg once weekly for first 4 weeks, then 1.5mg/kg once weekly.

Boxed Warning:

Thrombotic microangiopathy and thromboembolism.

Warnings/Precautions:

Thrombotic microangiopathy and thromboembolism can occur when average cumulative of >100U/kg per 24hrs of activated prothrombin complex concentrate (aPCC) was given for ≥24hrs. Females of reproductive potential should use effective contraception during treatment. Pregnancy. Nursing mothers.

Pharmacological Class:

Bispecific factor IXa- and factor X-directed antibody.

Interactions:

Risk of thrombotic microangiopathy and thromboembolism with concomitant aPCC; monitor and immediately discontinue if occurs. May interfere with coagulation lab tests (eg, ACT, aPTT, aPTT-based assays, Bethesda assays [clotting-based] for FVIII inhibitor titers). Possible hypercoagulability with concomitant recombinant FVIIa or FVIII.

Adverse Reactions:

Inj site reactions, headache, arthralgia, pyrexia, diarrhea, myalgia; thrombotic microangiopathy, thromboembolism.

Generic Availability:

NO

How Supplied:

Single-dose vial—1

Sign Up for Free e-newsletters